# uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies

> **NCT07109518** · PHASE1 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 12 (estimated)

## Conditions studied

- Acute Myeloid Leukemia (AML)
- T Lymphoblastic Leukemia/Lymphoma

## Interventions

- **BIOLOGICAL:** uCD7 CART

## Key facts

- **NCT ID:** NCT07109518
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-28
- **Primary completion:** 2028-06-28
- **Final completion:** 2030-06-28
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07109518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07109518, "uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07109518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*